These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19149518)

  • 1. Lessons from contaminated heparin.
    Dodd S; Besag FM
    Curr Drug Saf; 2009 Jan; 4(1):1. PubMed ID: 19149518
    [No Abstract]   [Full Text] [Related]  

  • 2. Contaminant in the recalled unfractionated heparin preparations: where is the problem?
    Hoppensteadt DA; Wahi R; Adiguzel C; Iqbal O; Ramacciotti E; Bick RL; Messmore HL; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):261-6. PubMed ID: 18565985
    [No Abstract]   [Full Text] [Related]  

  • 3. Tainted heparin crisis tested FDA's investigative skills.
    Lavine G
    Am J Health Syst Pharm; 2009 Feb; 66(3):210-1. PubMed ID: 19179633
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 5. Changes in the USP heparin monograph and implications for clinicians.
    Smythe MA; Nutescu EA; Wittkowsky AK
    Pharmacotherapy; 2010 May; 30(5):428-31. PubMed ID: 20411994
    [No Abstract]   [Full Text] [Related]  

  • 6. Heparin quality control in the Brazilian market: implications in the cardiovascular surgery.
    Melo EI; Pereira MS; Cunha RS; Sá MP; Mourão PA
    Rev Bras Cir Cardiovasc; 2008; 23(2):169-74. PubMed ID: 18820778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From crisis to opportunity: a perspective on the heparin crisis.
    Sasisekharan R; Shriver Z
    Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
    [No Abstract]   [Full Text] [Related]  

  • 8. Story of heparin recall: what India can do?
    Harugeri A; Parthasarathi G; Ramesh M; Sharma J; Padmini Devi D
    J Postgrad Med; 2008; 54(3):222-4. PubMed ID: 18626174
    [No Abstract]   [Full Text] [Related]  

  • 9. [Contaminated heparins].
    Monneret C
    Ann Pharm Fr; 2008 Aug; 66(4):212-5. PubMed ID: 18847567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
    Lindahl U
    Lakartidningen; 2008 Sep 24-30; 105(39):2660-1. PubMed ID: 18846871
    [No Abstract]   [Full Text] [Related]  

  • 12. The US regulatory and pharmacopeia response to the global heparin contamination crisis.
    Szajek AY; Chess E; Johansen K; Gratzl G; Gray E; Keire D; Linhardt RJ; Liu J; Morris T; Mulloy B; Nasr M; Shriver Z; Torralba P; Viskov C; Williams R; Woodcock J; Workman W; Al-Hakim A
    Nat Biotechnol; 2016 Jun; 34(6):625-30. PubMed ID: 27281424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sales of contaminated animal drugs halted.
    Henkel J
    FDA Consum; 1999; 33(5):34. PubMed ID: 10522171
    [No Abstract]   [Full Text] [Related]  

  • 14. Contaminated heparin preparations, severe adverse events and the contact system.
    Ramacciotti E; Wahi R; Messmore HL
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):489-91. PubMed ID: 18815138
    [No Abstract]   [Full Text] [Related]  

  • 15. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
    McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-focus on safety.
    Golembiewski J
    J Perianesth Nurs; 2008 Aug; 23(4):276-8. PubMed ID: 18657765
    [No Abstract]   [Full Text] [Related]  

  • 17. Combating counterfeit drugs.
    Lancet; 2008 May; 371(9624):1551. PubMed ID: 18468523
    [No Abstract]   [Full Text] [Related]  

  • 18. The troubled heparin issue in the Brazilian market and the search for solutions.
    Gomes WJ; Braile DM
    Rev Bras Cir Cardiovasc; 2009; 24(2):3-4. PubMed ID: 19768285
    [No Abstract]   [Full Text] [Related]  

  • 19. Many heparin-flush makers did not need manufacturing inspection.
    Thompson CA
    Am J Health Syst Pharm; 2008 Feb; 65(4):280. PubMed ID: 18238761
    [No Abstract]   [Full Text] [Related]  

  • 20. Heparin recall and India.
    Sharma V; Sharma A; Aggarwal S
    J Postgrad Med; 2008; 54(4):335-6. PubMed ID: 18953161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.